Yahoo Finance

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory ...

Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...
Yahoo Finance

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with ...

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...
Seeking Alpha

Lilly reports positive Phase 3 data for Jaypirca in CLL/SLL

Eli Lilly (NYSE:LLY) reported positive Phase 3 data from its BRUIN CLL-321 study of its drug pirtobrutunib, also known as Jaypirca, in the treatment adult patients with chronic lymphocytic leukemia, ...